We also decided to retain ESR1 and ERBB2, since their mutation prevalence increased gradually from primary tumor to extracerebral metastases and brain metastases (Table S4, Figure 2B and Figure 3), an observation that may have therapeutic implications. Here, ESR1 is linked to neoplasm.